Weight may influence breast cancer drug response, study suggests

NCT ID NCT02095184

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether body weight affects how breast cancer responds to aromatase inhibitors (AIs) like Anastrozole and Letrozole. Researchers gave standard doses of these drugs to 42 postmenopausal women with hormone-sensitive breast cancer before surgery. The goal was to see if overweight or obese women had a different anti-proliferative response compared to normal-weight women. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Anastrozole (Arimidex) and Letrozole (Femara)
What this could lead to
If successful, this could help doctors personalize aromatase inhibitor doses based on a patient's body weight, potentially improving treatment effectiveness for overweight or obese women with breast cancer.
What could go wrong
This was a small, early-stage study that was terminated, so results are limited. It may not provide clear answers, and findings may not apply to all breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.